Compare BOLT & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOLT | ZBAI |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.5M |
| IPO Year | 2021 | N/A |
| Metric | BOLT | ZBAI |
|---|---|---|
| Price | $7.01 | $7.20 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | ★ 21.3K | 10.2K |
| Earning Date | 11-12-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,195,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 93.55 |
| 52 Week Low | $4.41 | $4.83 |
| 52 Week High | $10.50 | $44.64 |
| Indicator | BOLT | ZBAI |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 51.96 |
| Support Level | $6.14 | $6.65 |
| Resistance Level | $6.60 | $7.21 |
| Average True Range (ATR) | 0.45 | 0.28 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 77.36 | 94.22 |
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.